[Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor]

Autor:	Søren, Fast, Emil, Henningsen, Anette, Bygum
Rok vydání:	2011
Předmět:	Enalapril Adrenergic beta-Antagonists Anti-Inflammatory Agents Non-Steroidal Humans Angiotensin-Converting Enzyme Inhibitors Female Angioedema Bradykinin Aged
Zdroj:	Ugeskrift for laeger. 173(41)
ISSN:	1603-6824
Popis:	A 78 year-old woman with life-threatening angiotensin-converting enzyme inhibitor (ACE-i) induced angioedema was unresponsive to conventional treatment with corticosteroids, antihistamines and epinephrine. She was successfully treated with icatibant licensed for treatment of hereditary angioedema knowing that both conditions involve bradykinin induced activation of bradykinin B2 receptors. Randomised, controlled trials are warranted to document the efficacy of icatibant in ACE-i angioedema.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::8122643cba9e2718e86896de155c5394 https://pubmed.ncbi.nlm.nih.gov/21985837 Zobrazit plný text záznamu